Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Sprint Bioscience

1.87 SEK

-2.86 %

Less than 1K followers

SPRINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Sprint Bioscience

2019202020212022202320242025
Revenue33.516.935.10.150.565.6167.2
growth-%-49.7 %108.0 %-99.8 %63,012.5 %30.0 %154.7 %
EBITDA-19.5-37.2-25.0-61.1-0.4-18.798.4
EBIT-20.2-37.8-25.6-60.7-0.9-19.797.3
Profit before taxes-21.5-42.8-25.1-60.2-0.4-18.391.7
Net income-21.5-42.8-25.1-60.2-0.4-18.391.7
EPS-1.41-2.03-0.71-1.41-0.01-0.260.99
Dividend0.000.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %0.0 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%-58.2 %-220.0 %-71.3 %-76,400.0 %-0.8 %-28.5 %58.8 %
EBIT-%-60.3 %-224.2 %-73.0 %-75,925.0 %-1.7 %-30.0 %58.2 %
ROE-195.5 %-468.0 %-35.6 %-213.4 %-2.1 %-197.2 %77.0 %
ROI-111.9 %-128.1 %-31.7 %-160.8 %-0.7 %-43.5 %67.1 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.